AVDL
AVADEL PHARMACEUTICALS PLC
No data for this timeframe.
Vol
Recent Activity
May 11, 2026
clinical_trial_readout
Results Pending: FT218 (Phase 3) — Completed 47d ago
Trial: Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
Sponsor: Avadel
Phase: Pha
Feb 12, 2026
Insider
Glass Geoffrey Michael sold 22,005 shares
Director @ $21.00 ($462.1K)
Feb 12, 2026
Insider
Glass Geoffrey Michael sold 60,000 shares
Director @ $0.00 ($0.00)
Feb 12, 2026
Insider
Rodriguez Susan sold 300,000 shares
Chief Operating Officer @ $0.00 ($0.00)
Analyst Ratings
2Strong Buy
4Buy
10Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 20, 2025 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
| Nov 7, 2025 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
| Oct 28, 2025 | UBS | DOWNGRADE | Buy → Neutral |
| Oct 23, 2025 | Leerink Partners | DOWNGRADE | Outperform → Market Perform |
| Oct 23, 2025 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 12, 2026 | Glass Geoffrey | D | $462.1K |
| Feb 12, 2026 | Glass Geoffrey | D | $0.00 |
| Feb 12, 2026 | Rodriguez Susan | D | $0.00 |
| Feb 12, 2026 | Thornton Peter | D | $2.4M |
| Feb 12, 2026 | Thornton Peter | D | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
10 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 12, 2026 | Glass Geoffrey Michael | Director | D | 22,005 | $21.00 | $462.1K |
| Feb 12, 2026 | Glass Geoffrey Michael | Director | D | 60,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Rodriguez Susan | Chief Operating Officer | D | 300,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Thornton Peter J. | Director | D | 115,060 | $21.00 | $2.4M |
| Feb 12, 2026 | Thornton Peter J. | Director | D | 60,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Seurer Jerad G. | Gen. Counsel & Corp. Secretary | D | 23,496 | $21.00 | $493.4K |
| Feb 12, 2026 | Seurer Jerad G. | Gen. Counsel & Corp. Secretary | D | 25,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Palczuk Linda | Director | D | 78,905 | $21.00 | $1.7M |
| Feb 12, 2026 | Palczuk Linda | Director | D | 60,000 | $0.00 | $0.00 |
| Feb 12, 2026 | MCHUGH THOMAS S | Chief Financial Officer | D | 100,400 | $21.00 | $2.1M |
| Feb 12, 2026 | MCHUGH THOMAS S | Chief Financial Officer | D | 250,000 | $0.00 | $0.00 |
| Feb 12, 2026 | McCamish Mark Anthony | Director | D | 22,000 | $21.00 | $462.0K |
| Feb 12, 2026 | McCamish Mark Anthony | Director | D | 60,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Ende Eric J | Director | D | 219,905 | $21.00 | $4.6M |
| Feb 12, 2026 | Ende Eric J | Director | D | 8,057 | $0.00 | $0.00 |
| Feb 12, 2026 | Divis Gregory J | Chief Executive Officer | D | 211,105 | $21.00 | $4.4M |
| Feb 12, 2026 | Divis Gregory J | Chief Executive Officer | D | 150,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Amin Naseem | Director | D | 22,000 | $21.00 | $462.0K |
| Feb 12, 2026 | Amin Naseem | Director | D | 49,500 | $0.00 | $0.00 |
| Feb 4, 2026 | McCamish Mark Anthony | Director | G | 67,025 | $0.00 | $0.00 |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Nov 2025): 38% buy across 16 analysts — 2 strong buy, 4 buy, 10 hold, 0 sell, 0 strong sell. No current recommendation available.
12 analyst firms have rated this stock: 0 upgrades, 5 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 20, 2025 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Nov 7, 2025 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Oct 28, 2025 | UBS | DOWNGRADE | Buy | Neutral |
| Oct 23, 2025 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Oct 23, 2025 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Oct 22, 2025 | Jefferies | DOWNGRADE | Buy | Hold |
| Oct 22, 2025 | Needham | DOWNGRADE | Buy | Hold |
| Sep 5, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Sep 3, 2025 | Wells Fargo | INITIATE | — | Equal-Weight |
| Aug 21, 2025 | UBS | MAINTAIN | Buy | Buy |
| Aug 8, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 8, 2025 | Needham | REITERATE | Buy | Buy |
| Apr 9, 2025 | Needham | REITERATE | Buy | Buy |
| Mar 4, 2025 | Needham | REITERATE | Buy | Buy |
| Mar 4, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 3, 2025 | Needham | REITERATE | Buy | Buy |
| Feb 11, 2025 | Deutsche Bank | INITIATE | — | Buy |
| Jan 13, 2025 | UBS | MAINTAIN | Buy | Buy |
| Jan 10, 2025 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 10, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 9, 2025 | Needham | MAINTAIN | Buy | Buy |
| Nov 12, 2024 | Needham | REITERATE | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 31, 2024 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Oct 31, 2024 | Needham | REITERATE | Buy | Buy |
| Apr 9, 2024 | Needham | REITERATE | Buy | Buy |
| Mar 5, 2024 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Mar 5, 2024 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Mar 5, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 5, 2024 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Mar 5, 2024 | Needham | MAINTAIN | Buy | Buy |
| Feb 6, 2024 | UBS | INITIATE | — | Buy |
| Dec 20, 2023 | Needham | MAINTAIN | Buy | Buy |
| Nov 9, 2023 | Needham | MAINTAIN | Buy | Buy |
| Oct 4, 2023 | Needham | REITERATE | Buy | Buy |
| Sep 25, 2023 | Needham | REITERATE | Buy | Buy |
| Aug 10, 2023 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Aug 10, 2023 | Needham | REITERATE | Buy | Buy |
| Aug 10, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 9, 2023 | Needham | REITERATE | — | Buy |
| Jul 5, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 30, 2023 | Oppenheimer | MAINTAIN | Outperform | Market Outperform |
| Jun 30, 2023 | Needham | REITERATE | Buy | Buy |
| Jun 12, 2023 | Oppenheimer | REITERATE | Outperform | Outperform |
| May 30, 2023 | Needham | REITERATE | — | Buy |
| May 2, 2023 | LifeSci Capital | MAINTAIN | — | Outperform |
| May 2, 2023 | Ladenburg Thalmann | MAINTAIN | — | Buy |
| May 2, 2023 | Oppenheimer | MAINTAIN | — | Outperform |
| May 2, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| May 2, 2023 | Needham | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 4 | 10 | 0 | 0 | 38% | |
| Apr 1, 2026 | 2 | 4 | 10 | 0 | 0 | 38% | |
| Mar 1, 2026 | 2 | 4 | 10 | 0 | 0 | 38% | |
| Feb 1, 2026 | 2 | 4 | 10 | 0 | 0 | 38% | |
| Jan 1, 2026 | 2 | 4 | 10 | 0 | 0 | 38% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
Clinical Trial
Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
Phase Phase 3 — COMPLETED
May 11, 2026
clinical_trial_readout
Results Pending: FT218 (Phase 3) — Completed 47d ago
Trial: Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
Sponsor: Avadel
Phase: Phase 3 | Completed: 2026-03-25
Conditions: Idiopathi
May 5, 2026
earnings_calendar
AVDL Q1 2026 Earnings Scheduled — 2026-05-05
Mar 9, 2026
earnings_calendar
AVDL Q4 2025 Earnings After Market Close — 2026-03-09
Feb 9, 2026
short_interest
FTD: AVDL — 27,394 shares ($0.6M) failed to deliver
Settlement: 20260209, Price: $21.69, FTD Value: $594,175.86, AVADEL PHARMACEUTICALS PLC ORD